- Algernon Pharmaceuticals (AGN) to conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research in London, UK
- Algernon’s Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of its proposed sub-psychedelic DMT dosages
- It plans to be the first company globally to test the use of prolonged intravenous DMT infusion at sub-psychedelic doses in humans
- Named the “Spirit Molecule,” DMT has been shown to induce neuroplasticity in several fundamental preclinical studies
- Algernon Pharmaceuticals (AGN) is in the grey and is trading at C$0.36 percent at 1:14 pm EST
Algernon Pharmaceuticals (AGN) is set to conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research in London, UK.
HMR is an internationally respected CRO with an industry-leading pharmacy, an on-site laboratory, and close clinical ties to Central Middlesex Hospital.
They also have direct experience with the administration of psychedelic agents.
Since 1993, HMR has completed more than 850 studies and has worked for most of the world’s major pharmaceutical and biotechnology companies.
Algernon’s Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of its proposed sub-psychedelic DMT dosages in healthy participants with no prior history of psychedelic exposure.
The study, designed to establish pharmacological baselines, is anticipated to begin as soon as it has cGMP drug products from its recently appointed drug manufacturer Dalton Pharma.
Although small clinical studies with DMT have been done in the past, Algernon is planning to be the first company globally to test the use of prolonged intravenous DMT infusion at sub-psychedelic doses in humans for potential stroke treatment applications.
The Phase 1 study will provide essential data on Algernon’s proposed dosing regimen and inform its planned Phase 2 trials in stroke patients.
“We are very pleased to have chosen HMR for our Phase 1 DMT study,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
“Our goal with our current aggressive clinical plan is to be in a Phase 2 Study in Q1 of 2022. We are committed as a Company to investigating DMT to learn if it can help stroke patients as quickly and as safely as possible,” added Moreau.
DMT is a hallucinogenic tryptamine drug-producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesized in a laboratory.
Named the “Spirit Molecule” by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, DMT has been shown to induce neuroplasticity in several fundamental preclinical studies.
Algernon will be investigating an intravenous sub-hallucinogenic dose of DMT in its research and clinical studies.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Algernon Pharmaceuticals (AGN) is in the grey and is trading at C$0.36 percent at 1:14 pm EST.
